Axovant Sciences Ltd (NASDAQ:AXON) was the target of some unusual options trading activity on Thursday. Stock traders acquired 6,684 put options on the company. This represents an increase of 2,511% compared to the average daily volume of 256 put options.

A number of research analysts recently weighed in on the stock. Chardan Capital reiterated a “sell” rating and issued a $3.00 price objective on shares of Axovant Sciences in a research note on Friday, October 6th. BidaskClub upgraded shares of Axovant Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, October 5th. Zacks Investment Research upgraded shares of Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $8.00 price target for the company in a research report on Monday, October 9th. HC Wainwright restated a “buy” rating on shares of Axovant Sciences in a research report on Thursday, October 19th. Finally, Oppenheimer restated a “hold” rating on shares of Axovant Sciences in a research report on Sunday, November 12th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $14.14.

Hedge funds have recently added to or reduced their stakes in the business. Federated Investors Inc. PA purchased a new position in shares of Axovant Sciences in the second quarter valued at about $1,408,000. Lord Abbett & CO. LLC purchased a new position in shares of Axovant Sciences in the second quarter valued at about $696,000. Bank of New York Mellon Corp increased its position in shares of Axovant Sciences by 27.0% in the second quarter. Bank of New York Mellon Corp now owns 102,664 shares of the biotechnology company’s stock valued at $2,380,000 after acquiring an additional 21,801 shares during the period. Janus Henderson Group PLC purchased a new position in shares of Axovant Sciences in the second quarter valued at about $47,854,000. Finally, OxFORD Asset Management LLP purchased a new position in shares of Axovant Sciences in the second quarter valued at about $2,141,000. Hedge funds and other institutional investors own 96.95% of the company’s stock.

Axovant Sciences (NASDAQ:AXON) traded down $0.01 during trading on Monday, reaching $2.15. 667,408 shares of the company’s stock traded hands, compared to its average volume of 2,200,000. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94. The company has a market capitalization of $231.58 and a P/E ratio of -0.93. Axovant Sciences has a 1-year low of $2.00 and a 1-year high of $27.98.

Axovant Sciences (NASDAQ:AXON) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.09). analysts predict that Axovant Sciences will post -2.17 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Marea Informative and is the property of of Marea Informative. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.mareainformativa.com/axovant-sciences-target-of-unusually-high-options-trading-axon-updated-updated-updated/125334/.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.